Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome (PERSUADE)
Weerts ZZRM, Masclee AAM, Witteman BJM, Clemens CHM, Winkens B, Brouwers JRBJ, Frijlink HW, Muris JWM, De Wit NJ, Essers BAB, Tack J, Snijkers JTW, Bours AMH, de Ruiter-van der Ploeg AS, Jonkers DMAE, Keszthelyi D
Published in Gastroenterology
Methodology
Multicenter randomized double-blind placebo-controlled trial of small-intestinal release and ileocolonic release peppermint oil for 8 weeks in IBS
Key Findings
Neither peppermint oil formulation met the primary endpoint of abdominal pain response versus placebo, although secondary endpoints improved with small-intestinal release
Conclusions
Peppermint oil did not significantly improve the primary IBS endpoint in this rigorous trial
Limitations
Possible high placebo response; endpoint definitions stricter than earlier trials
Supplements Studied
Neither peppermint oil formulation met the primary endpoint of abdominal pain response versus placebo, although secondary endpoints improved with small-intestinal release
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.